Biogen Inc. stock rises Friday, still underperforms market
Shares of Biogen Inc. BIIB inched 0.49% higher to $185.68 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.90% to 5,751.07 and ...
The Best Performing S&P 500 Stocks Over the Past 30 Years Might Surprise You
A performance analysis of the current constituents of the S&P 500 Index Over the Last 30 Years ending September 2024 ...
Biogen and its investors both want US appeals court to clarify class certification
In a rare – and possibly unique – turn of events, both pharmacy company Biogen and its shareholders have asked a federal ...
Indiatimes15d
Revolution or mirage? Controversy surrounds new Alzheimer's drugs
Lecanemab, sold under the name Leqembi, was developed by US pharma firms Biogen and Eisai. Donanemab, developed by pharma giant Eli Lilly, is sold as Kisunla.
Couriermail16d
Revolution or mirage? Controversy surrounds new Alzheimer's drugs
A doctor working for Eli Lilly, who spoke on condition of anonymity, blamed its rival Biogen for overstating the benefits of previous treatment Aduhelm. The drug was controversially approved in ...